269 related articles for article (PubMed ID: 19906796)
1. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
Higgins LS; Depaoli AM
Am J Clin Nutr; 2010 Jan; 91(1):267S-272S. PubMed ID: 19906796
[TBL] [Abstract][Full Text] [Related]
2. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
3. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
4. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?
DePaoli AM; Higgins LS; Henry RR; Mantzoros C; Dunn FL;
Diabetes Care; 2014 Jul; 37(7):1918-23. PubMed ID: 24722496
[TBL] [Abstract][Full Text] [Related]
5. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
7. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
[TBL] [Abstract][Full Text] [Related]
8. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
[TBL] [Abstract][Full Text] [Related]
9. Selective peroxisome proliferator-activated receptor-γ modulation to reduce cardiovascular risk in patients with insulin resistance.
Yew T; Toh SA; Millar JS
Recent Pat Cardiovasc Drug Discov; 2012 Apr; 7(1):33-41. PubMed ID: 22044303
[TBL] [Abstract][Full Text] [Related]
10. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
[TBL] [Abstract][Full Text] [Related]
11. Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.
Dunn FL; Higgins LS; Fredrickson J; DePaoli AM;
J Diabetes Complications; 2011; 25(3):151-8. PubMed ID: 20739195
[TBL] [Abstract][Full Text] [Related]
12. INT131: a selective modulator of PPAR gamma.
Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
Gelman L; Feige JN; Desvergne B
Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
[TBL] [Abstract][Full Text] [Related]
14. Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Leibowitz MD; Ardecky RJ; Boehm MF; Broderick CL; Carfagna MA; Crombie DL; D'Arrigo J; Etgen GJ; Faul MM; Grese TA; Havel H; Hein NI; Heyman RA; Jolley D; Klausing K; Liu S; Mais DE; Mapes CM; Marschke KB; Michellys PY; Montrose-Rafizadeh C; Ogilvie KM; Pascual B; Rungta D; Tyhonas JS; Urcan MS; Wardlow M; Yumibe N; Reifel-Miller A
Endocrinology; 2006 Feb; 147(2):1044-53. PubMed ID: 16269450
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
16. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
17. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
[TBL] [Abstract][Full Text] [Related]
18. [PPAR receptors and insulin sensitivity: new agonists in development].
Pégorier JP
Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S10-7. PubMed ID: 15959400
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
Derosa G
Drugs; 2010 Oct; 70(15):1945-61. PubMed ID: 20883052
[TBL] [Abstract][Full Text] [Related]
20. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
